Publikationen

Suche

Literaturliste Prof. Dr. med. Hans-Joachim Schmoll

FACT Datenbank des Universitätsklinikum Halle-Wittenberg

Journalbeitrag
Originalarbeiten

  1. Arnold D, Schmoll HJ, Lang H, Knoefel WT, Ridwelski K, Trarbach T, Staib L, Kirchner T, Geissler M, Seufferlein T, Amthauer H, Riess H, Schlitt HJ, Piso P: (2010) Spezielle Therapiesituationen beim metastasierten kolorektalen Karzinom. ONKOLOGIE, 33: 8-18
    IF: 1,156, anteiliger IF: 0,03212
     
  2. Bukur J, Loeffler D, Massa C, Mueller L, Riemann D, Schmoll HJ, Seliger B: (2010) "Tumor immunology meets oncology IV", 23rd and 24th May 2008 Martin Luther University Halle-Wittenberg, Halle, Germany. CANCER IMMUNOLOGY IMMUNOTHERAPY, 59: 955-62 18751976
    IF: 4,293, anteiliger IF: 0,28626
     
  3. Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S, Collette L, Lluch JR, Bokemeyer C, Schmoll HJ: (2010) A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). ANNALS OF ONCOLOGY, 22: 1054-1061
    IF: 6,452, anteiliger IF: 2,15045
     
  4. Jordan K, Grothey A, Pelz T, Lautenschläger C, Franke U, Schöber C, Schmoll HJ: (2010) Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting. EUROPEAN JOURNAL OF CANCER CARE, 19: 603-9 19725867
    IF: 1,138, anteiliger IF: 0,3793
     
  5. Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, Kegel T, Schmoll HJ: (2010) The NK-1 receptor-antagonist aprepitant in high-dose (HD) chemotherapy (HD melphalan and HD T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. BONE MARROW TRANSPLANTATION, 13: 1-6
    IF: 3,66, anteiliger IF: 1,21988
     
  6. Jordan K, Wolf HH, Voigt W, Kegel T, Mueller LP, Behlendorf T, Sippel C, Arnold D, Schmoll HJ: (2010) Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study. BONE MARROW TRANSPLANTATION, 45: 1704-9 20228848
    IF: 3,66, anteiliger IF: 1,21988
     
  7. Lützkendorf J, Müller LP, Müller T, Caysa H, Nerger K, Schmoll HJ: (2010) Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 14: 2292-304 19508388
    IF: 4,608, anteiliger IF: 1,53585
     
  8. Matuszczyk A, Petersen S, Voigt W, Kegel T, Dralle H, Schmoll HJ, Bockisch A, Mann K: (2010) Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium. HORMONE AND METABOLIC RESEARCH, 42: 61-4 19735058
    IF: 2,414, anteiliger IF: 0,13414
     
  9. Mueller T, Mueller LP, Holzhausen HJ, Witthuhn R, Albers P, Schmoll HJ: (2010) Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity. HISTOCHEMISTRY AND CELL BIOLOGY, 134: 197-204 20532795
    IF: 4,727, anteiliger IF: 1,57551
     
  10. Peinert S, Grothe W, Stein A, Müller LP, Ruessel J, Voigt W, Schmoll HJ, Arnold D: (2010) Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer. Therapeutic Advances in Medical Oncology, 2: 161-74 21789132
    IF: 0, anteiliger IF: 0
     
  11. Reinacher-Schick A, Arnold D, Trarbach T, Ridwelski K, Bruch HP, Kirchner T, Kubicka S, Schmoll HJ: (2010) Adjuvante Therapie des Kolonkarzinoms. ONKOLOGIE, 33: 2-7
    IF: 1,156, anteiliger IF: 0,38529
     
  12. Schmiegel W, Pox C, Reinacher-Schick A, Adler G, Arnold D, Fleig W, Fölsch UR, Frühmorgen P, Graeven U, Heinemann V, Hohenberger W, Holstege A, Junginger T, Kopp I, Kühlbacher T, Porschen R, Propping P, Riemann JF, Rödel C, Sauer R, Sauerbruch T, Schmitt W, Schmoll HJ, Seufferlein T, Zeitz M, Selbmann HK: (2010) S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). ZEITSCHRIFT FUR GASTROENTEROLOGIE, 48: 65-136 20072998
    IF: 1,131, anteiliger IF: 0,01571
     
  13. Schmoll HJ, Jordan K, Huddart R, Pes MPL, Horwich A, Fizazi K, Kataja V, ESMO Guidelines Working Group: (2010) Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY, 21 Suppl 5: v147-54 20555066
    IF: 6,452, anteiliger IF: 2,15045
     
  14. Schmoll HJ, Jordan K, Huddart R, Pes MPL, Horwich A, Fizazi K, Kataja V, ESMO Guidelines Working Group: (2010) Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY, 21 Suppl 5: v140-6 20555065
    IF: 6,452, anteiliger IF: 2,15045
     
  15. Van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, De Gramont A, Diaz-Rubio E, Ducreux M, Geva R, Glimelius B, Jones RG, Grothey A, Gruenberger T, Haller D, Haustermans K, Labianca R, Lenz HJ, Minsky B, Nordlinger B, Ohtsu A, Pavlidis N, Rougier P, Schmiegel W, van de Velde C, Schmoll HJ, Sobrero A, Tabernero J: (2010) Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona 2009. ANNALS OF ONCOLOGY, 21: v1-10
    IF: 6,452, anteiliger IF: 0,08273
     
  16. Voigt W, Lorenz K, Schmoll HJ: (2010) Therapie des Schilddrüsenkarzinoms. TUMORDIAGN THER, 1: 18-22
    IF: 0, anteiliger IF: 0
     
  17. Zwierzina H, Bardelli A, Ciardiello F, Gariboldi M, Hakansson L, Lambrechts D, Lind GE, Loeffler-Ragg J, Schmoll HJ, Siena S, Tabernero J, van Cutsem E: (2010) Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials. CURR OPIN MOL THER, 12: 703-11 21154162
    IF: 4,023, anteiliger IF: 0,13413
     

2010

Summe Bewertung = 13,45214

Summe IF = 57,774


Originalarbeiten

  1. Abouassaly R, Fossa SD, Giwercman A, Kollmannsberger C, Motzer RJ, Schmoll HJ, Sternberg CN: (2011) Sequelae of treatment in long-term survivors of testis cancer. EUROPEAN UROLOGY, 60: 516-26 21684072
    IF: 8,493, anteiliger IF: 0,56631
     
  2. Arnold D, Fietkau R, Hegewisch-Becker S, Höhler T, Knoefel WT, Kubicka S, Lang H, Liersch T, Luster M, Oettle H, Reinacher-Schick A, Ridwelski K, Riess H, Rödel C, Rüschoff J, Schmiegel W, Schmoll HJ, Vanhoefer U: (2011) Gastrointestinale Tumore - interdisziplinäre Diskussion neuer Daten. ONKOLOGIE, 34: 1-31
    IF: 0,868, anteiliger IF: 0,01809
     
  3. Arnold D, Fietkau R, Hegewisch-Becker S, Höhler T, Knoefel WT, Kubicka S, Lang H, Liersch T, Luster M, Oettle H, Reinacher-Schick A, Ridwelski K, Riess H, Rödel C, Rüschoff J, Schmiegel W, Schmoll HJ, Vanhoefer U: (2011) [Gastrointestinal tumors--interdisciplinary discussion over new data]. ONKOLOGIE, 34 Suppl 3: 1-31 21577036
    IF: 0,868, anteiliger IF: 0,01809
     
  4. Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S, Collette L, Lluch JRG, Bokemeyer C, Schmoll HJ: (2011) A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). ANNALS OF ONCOLOGY, 22: 1054-61 21059637
    IF: 6,425, anteiliger IF: 2,14145
     
  5. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll HJ: (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. JOURNAL OF CLINICAL ONCOLOGY, 29: 1465-71 21383294
    IF: 18,372, anteiliger IF: 6,12339
     
  6. Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, Kegel T, Schmoll HJ: (2011) The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. BONE MARROW TRANSPLANTATION, 46: 784-9 20838387
    IF: 3,746, anteiliger IF: 1,24854
     
  7. Keyszer G, Christopeit M, Fick S, Schendel M, Taute BM, Behre G, Müller LP, Schmoll HJ: (2011) Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases. ARTHRITIS RHEUM-US, 63: 2540-2 21547891
    IF: 7,866, anteiliger IF: 2,62174
     
  8. Rüssel J, Stein A, Behrmann C, Hauptmann S, Krummenerl P, Schmoll HJ, Arnold D: (2011) Inflammatory lesions of the peritoneum mimic carcinomatosis after treatment with intravenous chemotherapy and intraperitoneal catumaxomab. JOURNAL OF CLINICAL ONCOLOGY, 29: e644-6 21606410
    IF: 18,372, anteiliger IF: 1,22504
     
  9. Schmoll HJ, Heissner K: (2011) Current treatment of stage I testicular seminoma. ONKOLOGIE, 34: 495-6 21985846
    IF: 0,868, anteiliger IF: 0,434
     
  10. Schmoll HJ, Osanto S, Kawai K, Einhorn L, Fizazi K: (2011) Advanced seminoma and nonseminoma: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. UROLOGY, 78: S456-68 21986225
    IF: 2,428, anteiliger IF: 0,80925
     
  11. Stein A, Hiemer S, Schmoll HJ: (2011) Adjuvant therapy for early colon cancer: current status. DRUGS, 71: 2257-75 22085384
    IF: 4,226, anteiliger IF: 1,40853
     
  12. Surov A, Fiedler E, Holzhausen HJ, Ruschke K, Schmoll HJ, Spielmann RP: (2011) Metastases to the breast from non-mammary malignancies: primary tumors, prevalence, clinical signs, and radiological features. ACADEMIC RADIOLOGY, 18: 565-74 21393030
    IF: 1,692, anteiliger IF: 0,14103
     
  13. Tempero MA, Berlin J, Ducreux M, Haller D, Harper P, Khayat D, Schmoll HJ, Sobrero A, Van Cutsem E: (2011) Pancreatic cancer treatment and research: an international expert panel discussion. ANNALS OF ONCOLOGY, 22: 1500-6 21199884
    IF: 6,425, anteiliger IF: 0,30601
     
  14. Van Cutsem E, Dicato M, Geva R, Arber N, Bang Y, Benson A, Cervantes A, Diaz-Rubio E, Ducreux M, Glynne-Jones R, Grothey A, Haller D, Haustermans K, Kerr D, Nordlinger B, Marshall J, Minsky BD, Kang YK, Labianca R, Lordick F, Ohtsu A, Pavlidis N, Roth A, Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Van de Velde C, Zalcberg J: (2011) The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. ANNALS OF ONCOLOGY, 22 Suppl 5: v1-9 21633049
    IF: 6,425, anteiliger IF: 0,07934
     

2011

Summe Bewertung = 17,14081

Summe IF = 87,074


Originalarbeiten

  1. Calabrò F, Albers P, Bokemeyer C, Martin C, Einhorn LH, Horwich A, Krege S, Schmoll HJ, Sternberg CN, Daugaard G: (2012) The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. EUROPEAN UROLOGY, 61: 1212-21 22464311
    IF: 10,476, anteiliger IF: 0,43659
     
  2. de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, André T, Hoff PM: (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. LANCET ONCOLOGY, 13: 1225-33 23168362
    IF: 25,117, anteiliger IF: 0,46522
     
  3. Nagtegaal ID, Quirke P, Schmoll HJ: (2012) Has the new TNM classification for colorectal cancer improved care? Nature Reviews Clinical Oncology, 9: 119-23 22009076
    IF: 15,031, anteiliger IF: 5,00983
     
  4. Saini KS, Taylor C, Ramirez AJ, Palmieri C, Gunnarsson U, Schmoll HJ, Dolci SM, Ghenne C, Metzger-Filho O, Skrzypski M, Paesmans M, Ameye L, Piccart-Gebhart MJ, de Azambuja E: (2012) Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. ANNALS OF ONCOLOGY, 23: 853-9 21821551
    IF: 7,384, anteiliger IF: 0,20515
     
  5. Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E: (2012) Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). JOURNAL OF CLINICAL ONCOLOGY, 30: 3588-95 22965961
    IF: 18,038, anteiliger IF: 6,01207
     
  6. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A: (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. ANNALS OF ONCOLOGY, 23: 2479-516 23012255
    IF: 7,384, anteiliger IF: 2,46109
     
  7. Stein A, Glockzin G, Wienke A, Arnold D, Edelmann T, Hildebrandt B, Hollerbach S, Illerhaus G, Königsrainer A, Richter M, Schlitt HJ, Schmoll HJ: (2012) Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC CANCER, 12: 356 22897915
    IF: 3,333, anteiliger IF: 1,11089
     
  8. Stein A, Hiemer S, Jordan K, Arnold D, Schmoll HJ: (2012) Administration of chemotherapy by an arteriovenous fistula in a patient with metastatic rectal cancer after life-threatening, port thrombosis-associated cava superior syndrome. An option for patients without possibility of peripheral or central venous access. ONKOLOGIE, 35: 440-2 22846976
    IF: 1, anteiliger IF: 0,3333
     

2012

Summe Bewertung = 16,03414

Summe IF = 87,763


Originalarbeiten

  1. Aapro MS, Schmoll HJ, Jahn F, Carides AD, Webb RT: (2013) Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types. CANCER TREATMENT REVIEWS, 39: 113-7 23062719
    IF: 6,466, anteiliger IF: 0,71859
     
  2. Bernig T, Jahn F, Witkowsky S, Huehn R, Hentschel A, Kegel T, Schmoll HJ, Körholz D: (2013) Treatment of adolescents and young adults (AYA) with cancer in a multidisciplinary setting: on the way to a highly specialized AYA unit. KLINISCHE PADIATRIE, 225: 335-8 24166088
    IF: 0, anteiliger IF: 0
     
  3. Christopeit M, Janssen N, Weber T, Bacher U, Lautenschläger C, Oehme A, Kekulé AS, Schmoll HJ: (2013) Cyclosporine area under the curve after allogeneic hematopoietic stem cell transplantation is an indicator of Epstein-Barr virus DNAemia. LEUKEMIA & LYMPHOMA, 54: 133-7 22721496
    IF: 2,605, anteiliger IF: 0,86825
     
  4. Christopeit M, Lindner A, Surov A, Weber T, Vehreschild MJGT, Bialek R, Schmoll HJ: (2013) Right flank pain and high fever in a neutropenic patient with acute lymphoblastic leukaemia. MYCOSES, 56: 90-2 22889321
    IF: 1,805, anteiliger IF: 0,60161
     
  5. Dralle H, Musholt TJ, Schabram J, Steinmüller T, Frilling A, Simon D, Goretzki PE, Niederle B, Scheuba C, Clerici T, Hermann M, Kußmann J, Lorenz K, Nies C, Schabram P, Trupka A, Zielke A, Karges W, Luster M, Schmid KW, Vordermark D, Schmoll HJ, Mühlenberg R, Schober O, Rimmele H, Machens A, German Societies of General and Visceral Surgery Endocrinology Nuclear Medicine Pathology Radiooncology Oncological Hematology and the German Thyroid Cancer Patient Support Organization Ohne Schilddrüse leben e.V: (2013) German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. LANGENBECKS ARCHIVES OF SURGERY, 398: 347-75 23456424
    IF: 2,16, anteiliger IF: 0,02881
     
  6. Jürgensmeier JM, Schmoll HJ, Robertson JD, Brooks L, Taboada M, Morgan SR, Wilson D, Hoff PM: (2013) Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. BRITISH JOURNAL OF CANCER, 108: 1316-23 23449351
    IF: 4,817, anteiliger IF: 0,26766
     
  7. Oldenburg J, Fosså SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, Horwich A, Beyer J, Kataja V, ESMO Guidelines Working Group: (2013) Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY, 24 Suppl 6: vi125-32 24078656
    IF: 6,578, anteiliger IF: 0,2743
     
  8. Pox C, Aretz S, Bischoff SC, Graeven U, Hass M, Heußner P, Hohenberger W, Holstege A, Hübner J, Kolligs F, Kreis M, Lux P, Ockenga J, Porschen R, Post S, Rahner N, Reinacher-Schick A, Riemann JF, Sauer R, Sieg A, Scheppach W, Schmitt W, Schmoll HJ, Schulmann K, Tannapfel A, Schmiegel W, Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft e. V, Deutschen Krebshilfe e. V: (2013) [S3-guideline colorectal cancer version 1.0]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 51: 753-854 23955142
    IF: 1,671, anteiliger IF: 0,02055
     
  9. Schmiegel W, Reinacher-Schick A, Arnold D, Kubicka S, Freier W, Dietrich G, Geißler M, Hegewisch-Becker S, Tannapfel A, Pohl M, Hinke A, Schmoll HJ, Graeven U: (2013) Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. ANNALS OF ONCOLOGY, 24: 1580-7 23463625
    IF: 6,578, anteiliger IF: 0,19937
     
  10. Stein A, Schmoll HJ: (2013) Systemic treatment of liver metastases from colorectal cancer. Therapeutic Advances in Medical Oncology, 5: 193-203 23634197
    IF: 0, anteiliger IF: 0
     
  11. Van Cutsem E, Borràs JM, Castells A, Ciardiello F, Ducreux M, Haq A, Schmoll HJ, Tabernero J: (2013) Improving outcomes in colorectal cancer: where do we go from here? EUROPEAN JOURNAL OF CANCER, 49: 2476-85 23642327
    IF: 4,819, anteiliger IF: 0,26778
     
  12. van de Velde CJH, Aristei C, Boelens PG, Beets-Tan RGH, Blomqvist L, Borras JM, van den Broek CBM, Brown G, Coebergh JW, Cutsem EV, Espin E, Gore-Booth J, Glimelius B, Haustermans K, Henning G, Iversen LH, Han van Krieken J, Marijnen CAM, Mroczkowski P, Nagtegaal I, Naredi P, Ortiz H, Påhlman L, Quirke P, Rödel C, Roth A, Rutten HJT, Schmoll HJ, Smith J, Tanis PJ, Taylor C, Wibe A, Gambacorta MA, Meldolesi E, Wiggers T, Cervantes A, Valentini V, European Registration of Cancer Care: (2013) EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. EUROPEAN JOURNAL OF CANCER, 49: 2784-90 23769991
    IF: 4,819, anteiliger IF: 0,0459
     

2013

Summe Bewertung = 3,29282

Summe IF = 42,318


Originalarbeiten

  1. Bach AG, Schmoll HJ, Beckel C, Behrmann C, Spielmann RP, Wienke A, Abbas J, Surov A: (2014) Pulmonary embolism in oncologic patients: frequency and embolus burden of symptomatic and unsuspected events. ACTA RADIOLOGICA, 55: 45-53 23864061
    IF: 1,603, anteiliger IF: 0,08913
     
  2. Breugom AJ, Boelens PG, van den Broek CBM, Cervantes A, Van Cutsem E, Schmoll HJ, Valentini V, van de Velde CJH: (2014) Quality assurance in the treatment of colorectal cancer: the EURECCA initiative. ANNALS OF ONCOLOGY, 25: 1485-92 24671742
    IF: 7,04, anteiliger IF: 0,39142
     
  3. Chu E, Haller D, Cartwright T, Twelves C, Cassidy J, Sun W, Saif MW, McKenna E, Lee S, Schmoll HJ: (2014) Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial. BRITISH JOURNAL OF CANCER, 110: 1438-45 24548866
    IF: 4,836, anteiliger IF: 1,61184
     
  4. Kreissl MC, Jacob C, Führer D, Karges W, Luster M, Lux MP, Mann K, Mittendorf T, Schott M, Spitzweg C, Schmoll HJ: (2014) Best supportive care from the conservative/non-surgical perspective and its costs in the treatment of patients with advanced medullary thyroid cancer: results of a Delphi panel. Oncology Research and Treatment, 37: 316-22 24903762
    IF: 0, anteiliger IF: 0
     
  5. Lestuzzi C, Vaccher E, Talamini R, Lleshi A, Meneguzzo N, Viel E, Scalone S, Tartuferi L, Buonadonna A, Ejiofor L, Schmoll HJ: (2014) Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. ANNALS OF ONCOLOGY, 25: 1059-64 24558023
    IF: 7,04, anteiliger IF: 2,34643
     
  6. Riemann JF, Schröder C, Kallenbach M, Giersiepen K, Schmoll HJ: (2014) Benefits and risks of colorectal cancer screening. Oncology Research and Treatment, 37 Suppl 3: 11-20 25195828
    IF: 0, anteiliger IF: 0
     
  7. Schmoll HJ, Stein A: (2014) Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection. Nature Reviews Clinical Oncology, 11: 79-80 24445520
    IF: 14,18, anteiliger IF: 7,09
     
  8. Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S, Yothers G, Haller D: (2014) Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. LANCET ONCOLOGY, 15: 1481-1492 25456367
    IF: 24,69, anteiliger IF: 8,22918
     
  9. Schmoll HJ, Wittig B, Arnold D, Riera-Knorrenschild J, Nitsche D, Kroening H, Mayer F, Andel J, Ziebermayr R, Scheithauer W: (2014) Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 140: 1615-24 24816725
    IF: 3,081, anteiliger IF: 1,0269
     
  10. Stein A, Arnold D, Thuss-Patience PC, Moehler M, Grothe W, Seufferlein T, Reinacher-Schick A, Geissler M, Hofheinz RD, Schmoll HJ: (2014) Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study. ACTA ONCOLOGICA, 53: 392-8 24024696
    IF: 2,997, anteiliger IF: 0,9989
     
  11. van de Velde CJH, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L, Beets-Tan RGH, van den Broek CBM, Brown G, Van Cutsem E, Espin E, Haustermans K, Glimelius B, Iversen LH, van Krieken JH, Marijnen CAM, Henning G, Gore-Booth J, Meldolesi E, Mroczkowski P, Nagtegaal I, Naredi P, Ortiz H, Påhlman L, Quirke P, Rödel C, Roth A, Rutten H, Schmoll HJ, Smith JJ, Tanis PJ, Taylor C, Wibe A, Wiggers T, Gambacorta MA, Aristei C, Valentini V: (2014) EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. EUROPEAN JOURNAL OF CANCER, 50: 1.e1-1.e34 24183379
    IF: 5,417, anteiliger IF: 0,05417
     

2014

Summe Bewertung = 21,83797

Summe IF = 70,884


Originalarbeiten

  1. Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D: (2015) Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. ONCOLOGIST, 20: 450-8 25795636
    IF: 4,789, anteiliger IF: 0,39892
     
  2. Bauer A, Vordermark D, Seufferlein T, Schmoll HJ, Dralle H, Mau W, Unverzagt S, Boese S, Fach EM, Landenberger M: (2015) Trans-sectoral care in patients with colorectal cancer: Protocol of the randomized controlled multi-center trial Supportive Cancer Care Networkers (SCAN). BMC CANCER, 15: 997 26694748
    IF: 3,265, anteiliger IF: 0,13615
     
  3. Grünwald V, Keilholz U, Boehm A, Guntinas-Lichius O, Hennemann B, Schmoll HJ, Ivanyi P, Abbas M, Lehmann U, Koch A, Karch A, Zörner A, Gauler TC: (2015) TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). ANNALS OF ONCOLOGY, 26: 561-7 25527417
    IF: 9,269, anteiliger IF: 0,28085
     
  4. Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ, Tveit KM, Gibson F: (2015) A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clinical Colorectal Cancer, 14: 1-10 25579803
    IF: 3,09, anteiliger IF: 0,1718
     
  5. Haller DG, O'Connell MJ, Cartwright TH, Twelves CJ, McKenna EF, Sun W, Saif MW, Lee S, Yothers G, Schmoll HJ: (2015) Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. ANNALS OF ONCOLOGY, 26: 715-724 25595934
    IF: 9,269, anteiliger IF: 3,08936
     
  6. Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D: (2015) Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. LANCET ONCOLOGY, 16: 1355-69 26361971
    IF: 26,509, anteiliger IF: 0,5885
     
  7. Jahn F, Jordan K, Behlendorf T, Globig C, Schmoll HJ, Müller-Tidow C, Jordan B: (2015) Safety and Efficacy of Liposomal Cytarabine in the Treatment of Neoplastic Meningitis. ONCOLOGY, 89: 137-42 25791073
    IF: 2,152, anteiliger IF: 0,14354
     
  8. Renfro LA, Grothey A, Kerr D, Haller DG, André T, Van Cutsem E, Saltz L, Labianca R, Loprinzi CL, Alberts SR, Schmoll H, Twelves C, Yothers G, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group, Adjuvant Colon Cancer Endpoints ACCENT Group: (2015) Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†. ANNALS OF ONCOLOGY, 26: 950-958 25697217
    IF: 9,269, anteiliger IF: 0,2206
     
  9. Ruff P, Ferry DR, Lakomỳ R, Prausová J, Van Hazel GA, Hoff PM, Cunningham D, Arnold D, Schmoll HJ, Moiseyenko VM, McKendrick JJ, Ten Tije AJ, Vishwanath RL, Bhargava P, Chevalier S, Macarulla T, Van Cutsem E: (2015) Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. EUROPEAN JOURNAL OF CANCER, 51: 18-26 25466509
    IF: 6,163, anteiliger IF: 0,13682
     
  10. Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Hoersch S, Rittweger K, Haller DG: (2015) Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. JOURNAL OF CLINICAL ONCOLOGY, 33: 3733-40 26324362
    IF: 20,982, anteiliger IF: 6,9933
     
  11. Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frödin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Mauro DJ, Watkins DJ: (2015) A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. JNCI-Journal of the National Cancer Institute, 107: djv258 26405092
    IF: 11,37, anteiliger IF: 0,21035
     
  12. Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJA, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ: (2015) Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. JOURNAL OF CLINICAL ONCOLOGY, 33: 22-8 25385741
    IF: 20,982, anteiliger IF: 0,26857
     
  13. Wittig B, Schmidt M, Scheithauer W, Schmoll HJ: (2015) MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 94: 31-44 25577571
    IF: 5,039, anteiliger IF: 1,6795
     

2015

Summe Bewertung = 14,31826

Summe IF = 132,148


Originalarbeiten

  1. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EGE, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AWJM, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y: (2016) ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 1: e000097 27843641
    IF: 0, anteiliger IF: 0
     
  2. Ferreri AJM, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G, International Extranodal Lymphoma Study Group (IELSG): (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematology, 3: e217-27 27132696
    IF: 7,123, anteiliger IF: 0,06624
     
  3. Gormly KL, Coscia C, Wells T, Tebbutt N, Harvey JA, Wilson K, Schmoll HJ, Price T: (2016) MRI rectal cancer in Australia and New Zealand: An audit from the PETACC-6 trial. Journal of Medical Imaging and Radiation Oncology, 60: 607-615 27397855
    IF: 1,189, anteiliger IF: 0,06611
     
  4. Lutz MP, Zalcberg JR, Glynne-Jones R, Ruers T, Ducreux M, Arnold D, Aust D, Brown G, Bujko K, Cunningham C, Evrard S, Folprecht G, Gerard JP, Habr-Gama A, Haustermans K, Holm T, Kuhlmann KF, Lordick F, Mentha G, Moehler M, Nagtegaal ID, Pigazzi A, Pucciarelli S, Roth A, Rutten H, Schmoll HJ, Sorbye H, Van Cutsem E, Weitz J, Otto F: (2016) Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" [Eur J Cancer 63 (August 2016) 11-24]. EUROPEAN JOURNAL OF CANCER, 68: 208-209 27717654
    IF: 6,029, anteiliger IF: 0
     
  5. Lutz MP, Zalcberg JR, Glynne-Jones R, Ruers T, Ducreux M, Arnold D, Aust D, Brown G, Bujko K, Cunningham C, Evrard S, Folprecht G, Gerard JP, Habr-Gama A, Haustermans K, Holm T, Kuhlmann KF, Lordick F, Mentha G, Moehler M, Nagtegaal ID, Pigazzi A, Puciarelli S, Roth A, Rutten H, Schmoll HJ, Sorbye H, Van Cutsem E, Weitz J, Otto F: (2016) Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. EUROPEAN JOURNAL OF CANCER, 63: 11-24 27254838
    IF: 6,029, anteiliger IF: 0,07175
     
  6. Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A: (2016) Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. ANNALS OF ONCOLOGY, 27: 1746-53 27358379
    IF: 11,855, anteiliger IF: 0,26318
     
  7. Moehler M, Gepfner-Tuma I, Maderer A, Thuss-Patience PC, Ruessel J, Hegewisch-Becker S, Wilke H, Al-Batran SE, Rafiyan MR, Weißinger F, Schmoll HJ, Kullmann F, von Weikersthal LF, Siveke JT, Weusmann J, Kanzler S, Schimanski CC, Otte M, Schollenberger L, Koenig J, Galle PR: (2016) Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. BMC CANCER, 16: 699 27582078
    IF: 3,288, anteiliger IF: 0,05754
     
  8. Papamichael D, Renfro LA, Matthaiou C, Yothers G, Saltz L, Guthrie KA, Van Cutsem E, Schmoll HJ, Labianca R, André T, O'Connell M, Alberts SR, Haller DG, Kountourakis P, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group: (2016) Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. Journal of Geriatric Oncology, 7: 422-429 27468630
    IF: 2,852, anteiliger IF: 0,06788
     
  9. Quidde J, Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Lange T, Dietrich G, Stoehlmacher J, Reinacher A, Tannapfel A, Trarbach T, Marschner N, Schmoll HJ, Hinke A, Al-Batran SE, Arnold D: (2016) Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. ANNALS OF ONCOLOGY, 27: 2203-2210 27753609
    IF: 11,855, anteiliger IF: 0,24658
     
  10. Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ: (2016) Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. JOURNAL OF CLINICAL ONCOLOGY, 34: 144-50 26503203
    IF: 24,008, anteiliger IF: 0,36492
     
  11. Shah MA, Renfro LA, Allegra CJ, André T, de Gramont A, Schmoll HJ, Haller DG, Alberts SR, Yothers G, Sargent DJ: (2016) Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. JOURNAL OF CLINICAL ONCOLOGY, 34: 843-53 26811529
    IF: 24,008, anteiliger IF: 1,00113
     
  12. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJG, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D: (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. ANNALS OF ONCOLOGY, 27: 1386-422 27380959
    IF: 11,855, anteiliger IF: 0,08773
     
  13. Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R, Prausová J, Moiseyenko VM, van Hazel G, Cunningham D, Arnold D, Schmoll HJ, Ten Tije AJ, McKendrick J, Kröning H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E, Vishwanath RL, Macarulla T, Tabernero J: (2016) Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Targeted Oncology, 11: 383-400 26706237
    IF: 3,438, anteiliger IF: 0,05466
     
  14. Widder M, Lützkendorf J, Caysa H, Unverzagt S, Wickenhauser C, Benndorf RA, Schmoll HJ, Müller-Tidow C, Müller T, Müller LP: (2016) Multipotent mesenchymal stromal cells promote tumor growth in distinct colorectal cancer cells by a β1-integrin-dependent mechanism. INTERNATIONAL JOURNAL OF CANCER, 138: 964-75 26356035
    IF: 6,513, anteiliger IF: 0,27159
     

2016

Summe Bewertung = 2,61932

Summe IF = 120,042


Originalarbeiten

  1. Bleiberg H, Decoster G, de Gramont A, Rougier P, Sobrero A, Benson A, Chibaudel B, Douillard JY, Eng C, Fuchs C, Fujii M, Labianca R, Larsen AK, Mitchell E, Schmoll HJ, Sprumont D, Zalcberg J: (2017) A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group. ANNALS OF ONCOLOGY, 28: 922-930 28453700
    IF: 13,926, anteiliger IF: 0,30916
     
  2. Bonnetain F, Borg C, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Diaz-Rubio E, Douillard JY, Fuchs CS, Giantonio BJ, Goldberg R, Heinemann V, Koopman M, Labianca R, Larsen AK, Maughan T, Mitchell E, Peeters M, Punt CJA, Schmoll HJ, Tournigand C, de Gramont A: (2017) How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials. ANNALS OF ONCOLOGY, 28: 2077-2085 28430862
    IF: 13,926, anteiliger IF: 0,22142
     
  3. Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J, Laurent-Puig P, Taieb J, PETACC8 Study Investigators, Austrian Breast and Colorectal cancer Study Group (ABCSG), Belgian Group of Digestive Oncology (BGDO), Lone Nørgård Petersen, Fédération Francophone de Cancérologie Digestive (FFCD), Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER), Fédération Nationale des Centres de Lutte Contre le Cancer Association Européenne de Recherche en Oncologie (AERO), Arbeitsgemeinschaft Internistische Onkologie (AIO), Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD), Gruppo Oncologico dell'Italia Meridionale (GOIM), Istituto Oncologico Romagnolo (IOR), Gruppo Cooperativo Chirurgico Italiano (GOCCI), Gruppo Oncologico Nord Ovest (GONO), Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Gruppo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação Oncológica (GCCD APIO), Grupo Español para el Tratamiento de los Tumores Digestivos (TTD), John Allen Bridgewater: (2017) Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. EUROPEAN JOURNAL OF CANCER, 82: 16-24 28651158
    IF: 7,191, anteiliger IF: 0,0799
     
  4. Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G, International Extranodal Lymphoma Study Group (IELSG): (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematology, 4: e510-e523 29054815
    IF: 10,698, anteiliger IF: 0,08293
     
  5. Lützkendorf J, Wieduwild E, Nerger K, Lambrecht N, Schmoll HJ, Müller-Tidow C, Müller LP: (2017) Resistance for Genotoxic Damage in Mesenchymal Stromal Cells Is Increased by Hypoxia but Not Generally Dependent on p53-Regulated Cell Cycle Arrest. PLoS One, 12: e0169921 28081228
    IF: 2,766, anteiliger IF: 0,18449
     
  6. Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff PM, Kabbinavar FF, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent DJ, ARCAD Clinical Trials Program: (2017) Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. JOURNAL OF CLINICAL ONCOLOGY, 35: 1929-1937 28414610
    IF: 26,303, anteiliger IF: 0,33668
     
  7. Schaffrath J, Schmoll HJ, Voigt W, Müller LP, Müller-Tidow C, Mueller T: (2017) Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity. PLoS One, 12: e0178930 28591197
    IF: 2,766, anteiliger IF: 0,23041
     
  8. Schmidt H, Boese S, Bauer A, Landenberger M, Lau A, Stoll O, Schmoll HJ, Mauz-Koerholz C, Kuss O, Jahn P: (2017) Interdisciplinary care programme to improve self-management for cancer patients undergoing stem cell transplantation: a prospective non-randomised intervention study. EUROPEAN JOURNAL OF CANCER CARE, 26: ecc.12458 26857103
    IF: 2,409, anteiliger IF: 0,10046
     
  9. Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frodin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Watkins DJ: (2017) Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. INTERNATIONAL JOURNAL OF CANCER, 140: 431-439 27681944
    IF: 7,36, anteiliger IF: 0,14426
     

2017

Summe Bewertung = 1,6897

Summe IF = 87,345


Originalarbeiten

  1. Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M: (2018) Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. EUROPEAN JOURNAL OF CANCER, 100: 35-45 29936065
    IF: 6,68, anteiliger IF: 0,07415
     
  2. Grothey A, Tabernero J, Arnold D, De Gramont A, Ducreux MP, O'Dwyer PJ, Van Cutsem E, Bosanac I, Srock S, Mancao C, Gilberg F, Winter J, Schmoll HJ: (2018) Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL - a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy. ANNALS OF ONCOLOGY, 29 Suppl 8: viii714-viii715 32137979
    IF: 14,196, anteiliger IF: 4,73153
     
  3. Schmoll HJ, Arnold D, de Gramont A, Ducreux M, Grothey A, O'Dwyer PJ, Van Cutsem E, Hermann F, Bosanac I, Bendahmane B, Mancao C, Tabernero J: (2018) MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 144: 1197-1204 29644408
    IF: 3,332, anteiliger IF: 1,11067
     
  4. Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR, Fondation Aide et Recherche en Cancerologie Digestive Group: (2018) Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. JNCI-Journal of the National Cancer Institute, 110: 638-648 29267900
    IF: 10,211, anteiliger IF: 0,10636
     

2018

Summe Bewertung = 6,02271

Summe IF = 34,419


Originalarbeiten

  1. Burzykowski T, Coart E, Saad ED, Shi Q, Sommeijer DW, Bokemeyer C, Díaz-Rubio E, Douillard JY, Falcone A, Fuchs CS, Goldberg RM, Hecht JR, Hoff PM, Hurwitz H, Kabbinavar FF, Koopman M, Maughan TS, Punt CJA, Saltz L, Schmoll HJ, Seymour MT, Tebbutt NC, Tournigand C, Van Cutsem E, de Gramont A, Zalcberg JR, Buyse M, Aide et Recherche en Cancerologie Digestive Group: (2019) Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. JAMA Network Open, 2: e1911750 31539075
    IF: 5,032, anteiliger IF: 0,06441
     
  2. Mueller T, Freystein J, Lucas H, Schmoll HJ: (2019) Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model. MOLECULES, 24: 2865 31394786
    IF: 3,27, anteiliger IF: 1,08989
     

2019

Summe Bewertung = 1,1543

Summe IF = 8,302


Originalarbeiten

  1. Chibaudel B, Henriques J, Rakez M, Brenner B, Kim TW, Martinez-Villacampa M, Gallego-Plazas J, Cervantes A, Shim K, Jonker D, Guerin-Meyer V, Mineur L, Banzi C, Dewdney A, Dejthevaporn T, Bloemendal HJ, Roth A, Moehler M, Aranda E, Van Cutsem E, Tabernero J, Schmoll HJ, Hoff PM, André T, de Gramont A: (2020) Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial. JAMA Network Open, 3: e2020425 33074326
    IF: 8,483, anteiliger IF: 0,123
     
  2. Cohen R, Vernerey D, Bellera C, Meurisse A, Henriques J, Paoletti X, Rousseau B, Alberts S, Aparicio T, Boukovinas I, Gill S, Goldberg RM, Grothey A, Hamaguchi T, Iveson T, Kerr R, Labianca R, Lonardi S, Meyerhardt J, Paul J, Punt CJA, Saltz L, Saunders MP, Schmoll HJ, Shah M, Sobrero A, Souglakos I, Taieb J, Takashima A, Wagner AD, Ychou M, Bonnetain F, Gourgou S, Yoshino T, Yothers G, de Gramont A, Shi Q, André T, ACCENT Group: (2020) Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. EUROPEAN JOURNAL OF CANCER, 130: 63-71 32172199
    IF: 9,162, anteiliger IF: 0,08246
     
  3. Cremolini C, Antoniotti C, Stein A, Bendell J, Gruenberger T, Rossini D, Masi G, Ongaro E, Hurwitz H, Falcone A, Schmoll HJ, Di Maio M: (2020) Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. JOURNAL OF CLINICAL ONCOLOGY, unbekannt: JCO2001225 32816630
    IF: 44,544, anteiliger IF: 1,48332
     
  4. Gulhati P, Yin J, Pederson L, Schmoll HJ, Hoff P, Douillard JY, Hecht JR, Tournigand C, Tebbut N, Chibaudel B, Gramont AD, Shi Q, Overman MJ: (2020) Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA. JNCI-Journal of the National Cancer Institute, 112: 1127-1136 32191317
    IF: 13,506, anteiliger IF: 0,40923
     
  5. Schmoll HJ, Stein A, Van Cutsem E, Price T, Hofheinz RD, Nordlinger B, Daisne JF, Janssens J, Brenner B, Reinel H, Hollerbach S, Caca K, Fauth F, Hannig CV, Zalcberg J, Tebbutt N, Mauer ME, Marreaud S, Lutz MP, Haustermans K: (2020) Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. JOURNAL OF CLINICAL ONCOLOGY, Epub: Epub 33001764
    IF: 44,544, anteiliger IF: 14,84652
     

2020

Summe Bewertung = 16,94452

Summe IF = 120,239


Originalarbeiten

  1. Margalit O, Boursi B, Rakez M, Thierry A, Yothers G, Wolmark N, Haller DG, Schmoll HJ, Shi Q, Shacham-Shmueli E, de Gramont A: (2021) Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients. Clinical Colorectal Cancer, 2021: UNBEKANNT 33775561
    IF: 4,481, anteiliger IF: 0,1658
     
  2. Pietrantonio F, Fucà G, Rossini D, Schmoll HJ, Bendell JC, Morano F, Antoniotti C, Corallo S, Borelli B, Raimondi A, Marmorino F, Niger M, Boccaccino A, Masi G, Lonardi S, Boni L, de Braud F, Di Bartolomeo M, Falcone A, Cremolini C: (2021) FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. ONCOLOGIST, 26: 302-309 33336844
    IF: 5,55, anteiliger IF: 0,10268
     
  3. Schmoll HJ, Lindner LH, Reichardt P, Heißner K, Kopp HG, Kessler T, Mayer-Steinacker R, Rüssel J, Egerer G, Crysandt M, Kasper B, Niederwieser D, Kunitz A, Eigendorff E, Petersen I, Steighardt J, Cygon F, Meinert F, Stein A: (2021) Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. JAMA Oncology, 7: 255-262 33355646
    IF: 31,777, anteiliger IF: 10,59127
     
  4. Schmoll HJ, Mauer ME, Marreaud S, Stein A: (2021) Reply to P. Potemski and K. Bujko. JOURNAL OF CLINICAL ONCOLOGY, 39: 1306-1308 33621125
    IF: 44,544, anteiliger IF: 0
     

2021

Summe Bewertung = 10,85975

Summe IF = 86,352


Comments and Letter

  1. Schmoll HJ: (2010) S-1 for advanced colorectal cancer: do we need another oral fluorouracil prodrug? LANCET ONCOLOGY, 11: 808-809
    IF: 17,764, anteiliger IF: 1,7764
     

2010

Summe Bewertung = 1,7764

Summe IF = 17,764


Comments and Letter

  1. Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, Aust D, Baier P, Baretton G, Bernhardt J, Boeing H, Böhle E, Bokemeyer C, Bornschein J, Budach W, Burmester E, Caca K, Diemer WA, Dietrich CF, Ebert M, Eickhoff A, Ell C, Fahlke J, Feussner H, Fietkau R, Fischbach W, Fleig W, Flentje M, Gabbert HE, Galle PR, Geissler M, Gockel I, Graeven U, Grenacher L, Gross S, Hartmann JT, Heike M, Heinemann V, Herbst B, Herrmann T, Höcht S, Hofheinz RD, Höfler H, Höhler T, Hölscher AH, Horneber M, Hübner J, Izbicki JR, Jakobs R, Jenssen C, Kanzler S, Keller M, Kiesslich R, Klautke G, Körber J, Krause BJ, Kuhn C, Kullmann F, Lang H, Link H, Lordick F, Ludwig K, Lutz M, Mahlberg R, Malfertheiner P, Merkel S, Messmann H, Meyer HJ, Mönig S, Piso P, Pistorius S, Porschen R, Rabenstein T, Reichardt P, Ridwelski K, Röcken C, Roetzer I, Rohr P, Schepp W, Schlag PM, Schmid RM, Schmidberger H, Schmiegel WH, Schmoll HJ, Schuch G, Schuhmacher C, Schütte K, Schwenk W, Selgrad M, Sendler A, Seraphin J, Seufferlein T, Stahl M, Stein H, Stoll C, Stuschke M, Tannapfel A, Tholen R, Thuss-Patience P, Treml K, Vanhoefer U, Vieth M, Vogelsang H, Wagner D, Wedding U, Weimann A, Wilke H, Wittekind C, AWMF, AWMF: (2011) [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 49: 461-531 21476183
    IF: 0,896, anteiliger IF: 0,00028
     
  2. Schmoll HJ: (2011) Do we need oncology trials tailored for the elderly or frail? LANCET, 377: 1725-7 21601694
    IF: 38,278, anteiliger IF: 3,8278
     
  3. Schmoll HJ, Hallek M: (2011) Perspectives for onkologie. ONKOLOGIE, 34: 659 22156443
    IF: 0,868, anteiliger IF: 0,0434
     

2011

Summe Bewertung = 3,87148

Summe IF = 40,042


Comments and Letter

  1. Wass M, Behlendorf T, Schädlich B, Mottok A, Rosenwald A, Schmoll HJ, Jordan K: (2014) Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response. EUROPEAN JOURNAL OF HAEMATOLOGY, 92: 268-70 24330038
    IF: 2,066, anteiliger IF: 0,01377
     

2014

Summe Bewertung = 0,01377

Summe IF = 2,066


Comments and Letter

  1. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, ESMO/ASCO Global Curriculum Working Group: (2016) ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016. ANNALS OF ONCOLOGY, 27: 1378-81
    IF: 11,855, anteiliger IF: 0,39517
     
  2. Schmoll HJ: (2016) Targeting HER2: precision oncology for colorectal cancer. LANCET ONCOLOGY, 17: 685-686 27108244
    IF: 33,9, anteiliger IF: 3,39
     

2016

Summe Bewertung = 3,78517

Summe IF = 45,755


Comments and Letter

  1. Nagtegaal ID, Schmoll HJ: (2017) Colorectal cancer: What is the role of lymph node metastases in the progression of colorectal cancer? Nature Reviews Gastroenterology & Hepatology, 14: 633-634 28930293
    IF: 16,99, anteiliger IF: 0,8495
     
  2. Schmoll HJ: (2017) Selective internal radiotherapy in advanced colorectal cancer: only for right-sided tumours? LANCET ONCOLOGY, 18: 1138-1139 28781172
    IF: 36,418, anteiliger IF: 3,6418
     

2017

Summe Bewertung = 4,4913

Summe IF = 53,408


Comments and Letter

  1. Schmoll HJ: (2018) FOCUS4: a new trial design for evaluation of targeted drugs in colorectal cancer? Lancet Gastroenterology & Hepatology, 3: 143-145 29254888
    IF: 12,856, anteiliger IF: 1,2856
     

2018

Summe Bewertung = 1,2856

Summe IF = 12,856


Comments and Letter

  1. Schmoll HJ: (2020) The future of colorectal cancer research: an interview with Hans Schmoll. Future Oncology, 16: 2269-2271 33074748
    IF: 3,404, anteiliger IF: 0,3404